share_log

Needham Reiterates Buy on Cara Therapeutics, Maintains $5 Price Target

Benzinga ·  May 23 18:27

Needham analyst Joseph Stringer reiterates Cara Therapeutics (NASDAQ:CARA) with a Buy and maintains $5 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment